Bladder Pain Syndrome: US FDA Outlines A Different Approach To Personalized Medicine
Executive Summary
US FDA is following through on defining interstitial cystitis and bladder pain syndrome as a single condition – a move that runs counter to the trend towards more targeted, mechanistic definitions of disease. But the agency also offers a unique idea for endpoints that are truly personalized.
You may also be interested in...
Impersonal Medicine: IC/BPS And How An Orphan Indication Becomes A Common Disease
US FDA advisory committee recommendation to combine interstitial cystitis and bladder pain syndrome patients in clinical trials is an interesting example of encouraging drug development by broadening the patient population. That runs counter to the personalized medicine mantra of narrowing patient populations based on mechanism of action.
Bladder Pain, Interstitial Cystitis And The Move Toward Patient-Focused Drug Development
Patients with the conditions experience the same symptoms, US FDA advisory committee concludes. Industry sponsors had advocated for combined trials, but panel did not agree with firms' recommendations on study duration and outcome measures.
Medicare Reaffirms Faith In Formulary Review Process Ahead Of Part D Changes
Dramatic transformation in the US Medicare Part D benefit design does not require any changes to CMS’ overall approach to reviewing formulary submissions from private drug plan sponsors, the agency says in its final guidance implementing the design changes for 2025.